An S-caralol, its preparation method, and S-caralol hydrochloride

The preparation process of S-caralol was optimized by low-temperature nucleophilic substitution reaction. The reaction of (S)-1-chloro-3-isopropylamino-2-propanol with 4-hydroxycarbazole solved the problems of unstable chirality and complicated operation, and realized efficient preparation and industrial production of S-caralol.

CN123106515APending Publication Date: 2026-11-17NINGBO SANSHENG BIOLOGICAL TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611620677.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing S-caralol preparation process suffers from problems such as unstable chirality, difficulty in impurity control, complex operation, and unsuitability for industrial production.

Method used

A low-temperature nucleophilic substitution reaction was employed, using (S)-1-chloro-3-isopropylamino-2-propanol with 4-hydroxycarbazole. The reaction conditions were optimized by using a dehydrogenating reagent and a Finkelstein halogen exchange catalyst, and the feeding method was controlled to avoid high temperatures and the separation of intermediates in multiple steps.

Benefits of technology

It increases the enantiomeric excess value of S-caralol, reduces the risk of chiral changes, simplifies the process, and improves the stability and industrial applicability of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106515A_ABST
    Figure CN123106515A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of chiral drug synthesis technology, specifically relating to S-caralol, its preparation method, and S-caralol hydrochloride. The invention involves low-temperature nucleophilic substitution of a 4-hydroxycarbazole followed by dehydrogenation with an aminochlorool having a predetermined S-configuration in the presence of a Finkelstein halide exchange catalyst, combined with controlled feeding to promote intermolecular aryl etherification and reduce the risks of cyclization and chiral changes. The aminochlorool can be obtained from a chiral chlorodiol via selective oxidation and reductive amination. The resulting S-caralol is then salted and recrystallized to obtain S-caralol hydrochloride. This method eliminates the need for epoxide-based synthetic intermediates, enzyme catalysis, hydroxyl protection, and palladium hydrogenation on carbon, offering advantages such as good chirality retention, a simple process route, and ease of scale-up preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of chiral drug synthesis technology, specifically relating to S-caralol, its preparation method, and S-caralol hydrochloride. Background Technology

[0002] Caralanol is a carbazole β-adrenergic receptor blocker with a chiral center in its molecular structure. For such chiral compounds, obtaining the target configuration and maintaining optical purity during preparation are directly related to the consistency of product composition and quality control. Therefore, ensuring the effective preparation of the target product while reducing the generation of non-target configurations and related impurities, and improving the stability and scalability of the process, are key considerations in the preparation of S-caralanol and its pharmaceutical salts.

[0003] Existing technologies have disclosed various methods for preparing optically active caralolol. For example, US Patent 4697022A discloses a method for preparing optically active caralolol derivatives by reacting optically active epichlorohydrin or corresponding chiral epoxy compounds with 4-hydroxycarbazole to form a chiral carbazole intermediate, and then further reacting it with amine compounds. Chinese Patent CN101323580A discloses a method for synthesizing a class of chiral aryloxypropanolamine compounds, which also utilizes chiral halopropylene oxide and phenolic compounds to construct chiral intermediates, and then reacts them with amine compounds, listing S-caralolol as a target compound that can be prepared. The above methods indicate that S-caralolol can be synthesized by obtaining chiral building blocks in advance and then performing multiple subsequent transformations.

[0004] However, current S-caralol preparation processes still heavily rely on highly reactive epoxy raw materials or intermediates, requiring several intermediate conversion, separation, or purification processes. For multi-step synthesis with chiral centers, reaction conditions, intermediate stability, and subsequent processing conditions can all affect the yield, impurity composition, and optical purity of the final product, thus necessitating strict control over multiple stages during scale-up production. Furthermore, the numerous intermediate conversion and processing steps increase operational complexity and the difficulty of batch stability control. While existing technologies can yield optically active caralol, there is still room for improvement in balancing synthetic route simplicity, chirality preservation, intermediate stability, impurity control, and ease of industrial operation.

[0005] Therefore, it is necessary to develop an improved process for the preparation of S-caralol and its pharmaceutical salts, so as to reduce the process burden caused by the transformation and handling of complex intermediates, reduce the risk of side reactions and chiral loss, and improve the stability and industrial applicability of the preparation process while ensuring the optical purity and reaction yield of the target product. Summary of the Invention

[0006] To address the shortcomings of existing technologies, this invention proposes an S-caralol, its preparation method, and S-caralol hydrochloride. This invention provides an innovative solution that balances the reaction yield and chiral retention of S-caralol by performing low-temperature nucleophilic substitution with (S)-1-chloro-3-isopropylamino-2-propanol after hydrogen removal.

[0007] The first objective of this invention is achieved through the following technical solution:

[0008] A method for preparing S-caralol includes the following steps:

[0009] (1) Prepare a solution of 4-hydroxycarbazole with a concentration of 0.2~1 mol / L, and use a dehydrogenating agent to dehydrogenate the phenolic hydroxyl group of 4-hydroxycarbazole under inert gas protection. Stir at 0~30℃ for 0.5~3 h to obtain a phenol salt system. The hydrogen removal reagent used is any one or more of the following: sodium hydroxide, sodium carbonate, lithium hydroxide, lithium carbonate, cesium carbonate, sodium hydride, potassium hydroxide (KOH), potassium carbonate (K2CO3), lithium diisopropylamino (LDA), lithium hexamethyldisilamide (LiHMDS), sodium hexamethyldisilamide (NaHMDS), potassium hexamethyldisilamide (KHMDS), lithium methyl (LiMe), and n-butyllithium (n-BuLi). Based on the molar amount of the 4-hydroxycarbazole, the amount of the dehydrogenating agent is 0.5 to 2 equivalents; (2) Add Finkelstein halide exchange catalyst to the phenolic salt system, then add (S)-1-chloro-3-isopropylamino-2-propanol, and carry out nucleophilic substitution reaction at 0~30℃ for 8~36 h to obtain S-caralol; The Finkelstein halogen exchange catalyst is selected from any one or more of potassium iodide, sodium iodide, and tetrabutylammonium iodide; the amount of the Finkelstein halogen exchange catalyst is 5-30 mol based on the molar amount of the 4-hydroxycarbazole.

[0010] Preferably, the nucleophilic substitution reaction is carried out at a temperature of 15-25°C.

[0011] More preferably, the dehydrogenating agent is sodium hydride, LDA, LiHMDS, NaHMDS, KHMDS, LiMe, or n-BuLi.

[0012] More preferably, the dehydrogenating agent is LDA (lithium diisopropylaminodimethylamine).

[0013] Preferably, the amount of the dehydrogenating agent is 0.5 to 2 equivalents, based on the molar amount of the 4-hydroxycarbazole.

[0014] More preferably, the amount of the dehydrogenation reagent used is 0.8 to 1 equivalent.

[0015] Preferably, the nucleophilic substitution reaction is carried out in the presence of a Finkelstein halide exchange catalyst.

[0016] Preferably, based on the molar amount of the 4-hydroxycarbazole, the amount of the Finkelstein halide exchange catalyst is 5-30 mol.

[0017] More preferably, based on the molar amount of the 4-hydroxycarbazole, the amount of the Finkelstein halide exchange catalyst is 5-10 mol.

[0018] Preferably, the Finkelstein halide exchange catalyst is selected from any one or more of potassium iodide (KI), sodium iodide (NaI), and tetrabutylammonium iodide (TBAI).

[0019] More preferably, the Finkelstein halogen exchange catalyst is KI.

[0020] More preferably, the amount of KI used is 5~30 mol, based on the molar amount of the 4-hydroxycarbazole.

[0021] More preferably, based on the molar amount of the 4-hydroxycarbazole, the amount of KI used is 5~10 mol.

[0022] Preferably, the 4-hydroxycarbazole is added to a mixed solvent of acetonitrile and N,N-dimethylformamide to prepare a solution with a 4-hydroxycarbazole concentration of 0.2~1 mol / L, and the phenolic hydroxyl groups of the 4-hydroxycarbazole are subjected to dehydrogenation treatment using a dehydrogenation reagent under inert gas protection.

[0023] Preferably, the (S)-1-chloro-3-isopropylamino-2-propanol is prepared into a (S)-1-chloro-3-isopropylamino-2-propanol solution with a concentration of 0.2~3 mol / L, and added to the reaction system that has undergone dehydrogenation treatment and has been supplemented with Finkelstein halogen exchange catalyst at a volume feed rate of 1~10 mL / h to carry out a nucleophilic substitution reaction.

[0024] More preferably, the (S)-1-chloro-3-isopropylamino-2-propanol solution uses acetonitrile as a solvent.

[0025] More preferably, the concentration of the (S)-1-chloro-3-isopropylamino-2-propanol solution is 0.5~1.0 mol / L.

[0026] More preferably, the volumetric feeding rate of the (S)-1-chloro-3-isopropylamino-2-propanol solution is 4~8 mL / h.

[0027] Preferably, in step (1), the 4-hydroxycarbazole is added to a solvent to prepare a solution with a 4-hydroxycarbazole concentration of 0.2~1 mol / L. The solvent is used for both the dehydrogenation treatment in step (1) and the nucleophilic substitution reaction in step (2).

[0028] More preferably, the solvent is selected from any one or more of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetone, acetonitrile, N-methylpyrrolidone, dichloromethane, toluene, tetrahydrofuran, and 2-methyltetrahydrofuran.

[0029] More preferably, the solvent is an acetonitrile-DMF mixed solvent with a volume ratio of acetonitrile:DMF = 9:1 to 4:6.

[0030] In a further preferred embodiment, the volume ratio of the acetonitrile-DMF mixed solvent is acetonitrile:DMF = 5:5~4:6.

[0031] Preferably, the molar ratio of the 4-hydroxycarbazole to the (S)-1-chloro-3-isopropylamino-2-propanol is 1.0 to 1.5:1.

[0032] More preferably, the molar ratio of the 4-hydroxycarbazole to the (S)-1-chloro-3-isopropylamino-2-propanol is 1.0~1.2:1.

[0033] Preferably, 4-hydroxycarbazole is added to a mixed solvent of acetonitrile and N,N-dimethylformamide, and the phenolic hydroxyl group of 4-hydroxycarbazole is dehydrogenated using a dehydrogenating agent under inert gas protection, and stirred at 0~30℃ for 0.5~3 h; then Finkelstein halide exchange catalyst is added to the dehydrogenated reaction system, and (S)-1-chloro-3-isopropylamino-2-propanol is added to carry out a nucleophilic substitution reaction.

[0034] More preferably, the inert gas is selected from any one of nitrogen, argon and helium.

[0035] More preferably, the temperature of the hydrogen removal treatment is 0–30°C, and the stirring time is 0.5–3 h.

[0036] More preferably, the temperature for forming the phenolic salt system is 15~25℃, and the stirring time is 1~2 h.

[0037] Preferably, the nucleophilic substitution reaction takes 8 to 36 hours.

[0038] More preferably, the nucleophilic substitution reaction takes 8 to 24 hours.

[0039] Preferably, the preparation method further includes a post-processing step, which includes: after the nucleophilic substitution reaction is completed, water is added to the reaction system, and the system is extracted twice with ethyl acetate. The ethyl acetate is washed with water, washed with saturated NaCl aqueous solution and dried with anhydrous Na2SO4, filtered and concentrated to obtain a crude product, and then recrystallized with ethyl acetate-petroleum ether to obtain S-caralol.

[0040] More preferably, the recrystallization is carried out using a mixed solvent of ethyl acetate and petroleum ether.

[0041] More preferably, the volume ratio of ethyl acetate to petroleum ether is 3:1 to 10:1.

[0042] Preferably, the (S)-1-chloro-3-isopropylamino-2-propanol is prepared by the following method:

[0043] (1) In the presence of iron salt, nitrogen and oxygen free radical catalyst and regulator, the terminal primary hydroxyl group of (S)-3-chloro-1,2-propanediol is oxidized by using any one or two of air and oxygen as oxidant to obtain (S)-3-chloro-2-hydroxypropanal.

[0044] (2) The (S)-3-chloro-2-hydroxypropanal obtained in step (1) is subjected to reductive amination with isopropylamine in the presence of a reducing agent to obtain the (S)-1-chloro-3-isopropylamino-2-propanol.

[0045] Preferably, the iron salt is selected from ferric nitrate nonhydrate (Fe(NO3)3·9H2O).

[0046] Preferably, the nitrogen oxide free radical catalyst is selected from any one or more of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxo radical (4-OH-TEMPO) and TEMPO.

[0047] More preferably, the nitrogen oxide free radical catalyst is 4-OH-TEMPO.

[0048] Preferably, the regulator is selected from any one or both of sodium chloride (NaCl) and lithium chloride (LiCl).

[0049] More preferably, the regulator is NaCl.

[0050] Preferably, the reducing agent is selected from sodium triacetoxyborohydride (NaBH(OAc)3) and sodium borohydride, sodium cyanoborohydride, or any one or more of these.

[0051] More preferably, the reducing agent is NaBH(OAc)3.

[0052] Preferably, based on the molar amount of (S)-3-chloro-1,2-propanediol, the amount of iron salt is 5-20 mol%, the amount of nitroxide free radical catalyst is 2-30 mol%, the amount of regulator is 5-20 mol%, the amount of isopropylamine is 100-300 mol%, and the amount of reducing agent is 100-300 mol.

[0053] More preferably, based on the molar amount of (S)-3-chloro-1,2-propanediol, the amount of iron salt is 5-10 mol%, the amount of nitroxide free radical catalyst is 5-10 mol%, the amount of regulator is 5-10 mol%, the amount of isopropylamine is 150-200 mol%, and the amount of reducing agent is 100-200 mol.

[0054] Preferably, in step (1), the solvent for oxidation is selected from any one of 1,2-dichloroethane, dichloromethane, and toluene.

[0055] More preferably, in step (1), the solvent for oxidation is 1,2-dichloroethane.

[0056] Preferably, in step (1), the oxidation reaction temperature is 0~30℃.

[0057] More preferably, in step (1), the oxidation reaction temperature is 15~25℃.

[0058] Preferably, in step (1), the oxidant is either air or oxygen.

[0059] More preferably, when the oxidant is oxygen, the oxygen is introduced into the reaction system under normal pressure.

[0060] Preferably, after the oxidation reaction in step (1) is completed, an organic phase containing the (S)-3-chloro-2-hydroxypropanal is obtained by quenching and separation. The organic phase is used directly for the reductive amination in step (2) without concentration or separation of the (S)-3-chloro-2-hydroxypropanal.

[0061] In a further preferred embodiment, after the oxidation reaction in step (1) is completed, the residual oxidant is quenched with an aqueous sodium sulfite solution, and then water is added for separation.

[0062] More preferably, the sodium sulfite aqueous solution is a saturated sodium sulfite aqueous solution.

[0063] More preferably, when the solvent for oxidation in step (1) is 1,2-dichloroethane, the 1,2-dichloroethane organic phase containing (S)-3-chloro-2-hydroxypropanal obtained by separation is dried with anhydrous sodium sulfate and then used directly for the reductive amination in step (2) without concentration or separation of (S)-3-chloro-2-hydroxypropanal.

[0064] Preferably, in step (2), the reaction temperature of the reductive amination is 0~25℃.

[0065] More preferably, in step (2), the reaction temperature of the reductive amination is 10~25℃.

[0066] Preferably, in step (2), isopropylamine is added after the organic phase containing (S)-3-chloro-2-hydroxypropanal is cooled, and then the reducing agent is added for reductive amination.

[0067] Further preferably, the reaction system temperature when isopropylamine is added is 0~30℃.

[0068] More preferably, the reaction system temperature when isopropylamine is added is 15~25℃.

[0069] More preferably, after adding isopropylamine, the mixture is stirred for 0.5 to 6 hours before adding the reducing agent.

[0070] More preferably, after adding isopropylamine, the mixture is stirred for 0.5 to 4 hours before adding the reducing agent.

[0071] Preferably, the reducing agent is added to the reaction system in 3 to 5 batches.

[0072] More preferably, the time interval between the addition of two adjacent batches of the reducing agent is 20 to 40 minutes.

[0073] Preferably, after the reducing agent is added, a reducing amination reaction is carried out at 10~30℃ for 2~10h.

[0074] More preferably, after the reducing agent is added, a reducing amination reaction is carried out at 15~25℃ for 2~6 h.

[0075] Preferably, after the reductive amination reaction in step (2) is completed, the reaction is quenched using an aqueous solution of sodium bicarbonate.

[0076] More preferably, the sodium bicarbonate aqueous solution is a saturated sodium bicarbonate aqueous solution.

[0077] In a further preferred embodiment, the organic phase obtained after quenching and separation is washed sequentially with dilute hydrochloric acid aqueous solution, saturated sodium bicarbonate aqueous solution and saturated brine, and then dried with anhydrous sodium sulfate and desolventized at low temperature to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0078] More preferably, the concentration of the dilute hydrochloric acid aqueous solution is 0.5~5 mol / L.

[0079] More preferably, the temperature for depressurized low-temperature solvent removal is 10~35℃.

[0080] Preferably, the crude (S)-1-chloro-3-isopropylamino-2-propanol obtained is used directly in the nucleophilic substitution reaction without distillation purification.

[0081] This scheme first yields (S)-1-chloro-3-isopropylamino-2-propanol with a predetermined S configuration through selective oxidation and reductive amination of (S)-3-chloro-1,2-propanediol, followed by low-temperature nucleophilic substitution with 4-hydroxycarbazole. Building upon this scheme, the use of suitable dehydrogenating reagents, Finkelstein halogen exchange catalysts, and controlled feeding methods facilitates intermolecular aryl etherification and reduces the risk of intramolecular cyclization and chiral changes in aminochlorools. Furthermore, the hydroxyaldehyde obtained in the previous step is directly reductively amination without separation, and the resulting aminochlorool, after low-temperature solvent removal, is used directly for subsequent nucleophilic substitution without distillation purification. This reduces intermediate separation and purification processes and high-temperature treatment, which is beneficial for maintaining chirality and process continuity. Thus, S-caralol can be prepared without using epoxide-based synthetic intermediates, enzyme catalysis, hydroxyl protection, or palladium-on-carbon hydrogenation.

[0082] The second objective of this invention is achieved through the following technical solution:

[0083] An S-caralol, wherein the S-caralol is prepared by the above-described method for preparing S-caralol.

[0084] Preferably, the enantiomeric excess value (ee value) of the S-caralol is 90%~100%.

[0085] More preferably, the ee value of the S-Caralol is 95%~100%.

[0086] More preferably, the ee value of the S-Caralol is 98%~100%.

[0087] This scheme uses chiral starting materials with a predetermined S-configuration for subsequent transformation. By controlling the basicity, reaction temperature, and feeding method of the nucleophilic substitution reaction, the risk of chiral changes during the reaction is reduced, thus maintaining a high enantiomeric excess value for the obtained S-caralol. Further employing suitable dehydrogenating reagents, Finkelstein halide exchange catalysts, and controlled feeding methods can further reduce intramolecular cyclization and chiral loss, thereby further increasing the ee value of the obtained S-caralol.

[0088] The third objective of this invention is achieved through the following technical solution:

[0089] An S-caralol hydrochloride preparation method comprising the following steps:

[0090] The S-caralol obtained by the above preparation method was reacted with hydrogen chloride in an organic solvent to form a salt, and then recrystallized to obtain S-caralol hydrochloride.

[0091] Preferably, the organic solvent is selected from any one of methanol, ethanol, and isopropanol.

[0092] More preferably, the organic solvent is ethanol.

[0093] Preferably, the temperature of the salt formation reaction is 0~25℃.

[0094] More preferably, the temperature of the salt formation reaction is 0~5℃.

[0095] Preferably, the amount of HCl used is 1 to 2 equivalents, based on the molar amount of S-caralol.

[0096] More preferably, the amount of HCl used is 1 to 1.1 equivalents, based on the molar amount of S-caralol.

[0097] Preferably, after the salt formation reaction is completed, crystallization is carried out at a temperature of 0~10℃.

[0098] More preferably, the crystallization temperature is 0~5℃.

[0099] This method involves reacting the aforementioned S-caralol with HCl to form a salt, followed by recrystallization to obtain S-caralol hydrochloride. The salt formation process is used to convert the free base into hydrochloride, and recrystallization helps to further remove related impurities. By controlling the salt formation, crystallization, and recrystallization conditions, the adverse effects of post-processing on the quality of the chiral product can be reduced, thereby facilitating the acquisition of S-caralol hydrochloride with stable quality.

[0100] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0101] 1. This invention uses (S)-1-chloro-3-isopropylamino-2-propanol and 4-hydroxycarbazole as raw materials. After dehydrogenation, a phenolate is formed, which is then subjected to a nucleophilic substitution reaction at a relatively low temperature to directly construct the aryl ether structure of S-caralol. This method uses an aminochlorool with a predetermined S configuration as a chiral intermediate, which is beneficial for maintaining the chiral configuration during the formation of the aryl ether bond and reduces the risk of side reactions and chiral changes under high-temperature conditions.

[0102] 2. This invention further optimizes the dehydrogenating reagent, the Finkelstein halogen exchange catalyst, and the feeding method, enabling intermolecular nucleophilic substitution between the nucleophilic active species formed by 4-hydroxycarbazole and the aminochlorool under relatively mild conditions. Specifically, the preferred dehydrogenating reagent system helps reduce epoxide side reactions, the Finkelstein halogen exchange catalyst enhances the reactivity of the terminal halogenated groups, and controlled feeding promotes intermolecular aryl etherification, thereby improving reaction selectivity and preserving chirality.

[0103] 3. This invention also provides a method for preparing the (S)-1-chloro-3-isopropylamino-2-propanol, using (S)-3-chloro-1,2-propanediol as a chiral starting material, and obtaining the aminochlorool through selective oxidation and reductive amination. By controlling the oxidation system, reductive amination conditions, and intermediate processing methods, it is beneficial to maintain the original chiral center. Specifically, the obtained aminochlorool, after removing the reaction solvent under reduced pressure and low temperature, is used directly in the subsequent nucleophilic substitution reaction without distillation purification. This reduces the need for intermediate separation and purification operations and avoids the high-temperature treatment required for atmospheric distillation due to its high boiling point. This helps to reduce chiral changes and related side reaction risks, allowing the aforementioned intermediate preparation process to be seamlessly integrated with the subsequent nucleophilic substitution process.

[0104] 4. The S-caralol prepared by this invention has a high enantiomeric excess value, which can better maintain the target S configuration. By characterizing the enantiomeric excess value of the obtained S-caralol, the chirality retention during the preparation process can be further reflected, providing a basis for the product quality control of S-caralol.

[0105] 5. In this invention, the obtained S-caralol is further reacted with hydrogen chloride to form a salt, and then recrystallized to obtain S-caralol hydrochloride. The salt formation and recrystallization processes facilitate the acquisition of stable S-caralol hydrochloride and establish a complete technical system from the preparation of chiral intermediates and the formation of S-caralol to the preparation of hydrochloride, demonstrating good process implementation and industrial application value. Attached Figure Description

[0106] Figure 1 The HPLC spectrum of the racemic mixture of caralol hydrochloride;

[0107] Figure 2The chiral HPLC spectrum of S-caralol hydrochloride prepared in Example 1;

[0108] Figure 3 The high-resolution mass spectrometry (HRMS) spectrum of S-caralol hydrochloride prepared in Example 1;

[0109] Figure 4 S-caralol hydrochloride prepared in Example 1 1 H NMR spectrum;

[0110] Figure 5 S-caralol hydrochloride prepared in Example 1 13 C NMR spectrum;

[0111] Figure 6 Differential scanning calorimetry (DSC) curve of S-caralol hydrochloride prepared in Example 1;

[0112] Figure 7 The HPLC chromatogram of the purity of S-caralol hydrochloride prepared in Example 1 is shown. Detailed Implementation

[0113] The following will provide a clear and complete description of the concept, specific structure, and technical effects of the present invention in conjunction with the embodiments and accompanying drawings, so as to fully understand the purpose, solution, and effects of the present invention. It should be noted that, unless otherwise specified, the embodiments and features described in the embodiments of the present invention can be combined with each other.

[0114] In this invention, S-caralol refers to the S-configuration caralol that has not formed a salt with an acid, i.e., the free base of S-caralol. The terms S-caralol and the free base of S-caralol are different representations of the same compound and are distinct from S-caralol hydrochloride.

[0115] (S)-1-chloro-3-isopropylamino-2-propanol yield = (S)-1-chloro-3-isopropylamino-2-propanol crude product mass ÷ [(S)-3-chloro-1,2-propanediol mass ÷ M1 × M2] × 100%;

[0116] M1 = (S)-3-chloro-1,2-propanediol Relative molecular weight: 110

[0117] M2 = (S)-1-chloro-3-isopropylamino-2-propanol; relative molecular weight: 151;

[0118] Yield of S-caralol free base = Product mass of S-caralol free base ÷ [Mass of crude (S)-1-chloro-3-isopropylamino-2-propanol) ÷ M2 × M3] × 100%;

[0119] M3=S-Caralol relative molecular weight: 298;

[0120] Yield of S-caralol hydrochloride = Product mass of S-caralol hydrochloride ÷ [Free base of S-caralol ÷ M3 × M4] × 100%;

[0121] The relative molecular weight of M4=S-caralol hydrochloride is 334.

[0122] The materials used in the embodiments and comparative examples of this invention are described below:

[0123] (S)-3-chloro-1,2-propanediol, with a purity of 99% and an ee value of 99%, was purchased from Shanghai Titan Technology Co., Ltd., with product specification / item number 016240501.

[0124] 4-Hydroxycarbazole, with a purity of 98%, was purchased from Shanghai Titan Technology Co., Ltd., product specification / item number 013258199;

[0125] 4-OH-TEMPO, with a purity of 98%, was purchased from Shanghai Titan Technology Co., Ltd., product specification / item number 01270483;

[0126] Fe(NO3)3·9H2O, with a purity of 99%, was purchased from Shanghai Titan Technology Co., Ltd., with product specification / item number 016257165.

[0127] NaBH(OAc)3, purchased from Shanghai Titan Technology Co., Ltd., product specification / item number is 01089112;

[0128] LDA (lithium diisopropylamino), 2 mol / L, was purchased from Anhui Zesheng Technology Co., Ltd., product specification / item number W4300305000;

[0129] KOH, with a purity of 90%, was purchased from Shanghai Titan Technology Co., Ltd., product specification / item number 011377650;

[0130] KI, with a purity of 99%, was purchased from Shanghai Titan Technology Co., Ltd., product specification / item number 01113743;

[0131] Anhydrous acetonitrile, with a purity of 99% and a moisture content of ≤50ppm, was purchased from Shanghai Titan Technology Co., Ltd., product specification / item number 016929219;

[0132] The racemic mixture of caralol hydrochloride, with a purity of 95%, was purchased from Beijing Bailingwei Technology Co., Ltd., product specification / item number CCAD300968.

[0133] Example 1

[0134] The preparation method of S-caralol hydrochloride in Example 1 includes the following steps:

[0135] (1) 11 g of (S)-3-chloro-1,2-propanediol (99% ee) with an ee value of 100 mmol was added to a 250 mL three-necked reaction flask. 120 mL of 1,2-dichloroethane was added, followed by 5 mmol of Fe(NO3)3·9H2O, 5 mmol of 4-OH-TEMPO, and 10 mmol of NaCl to replace the air in the reaction system with oxygen. The reaction was stirred at 20 °C. The reaction was monitored by TLC, and the reaction was stopped when the starting material spot disappeared.

[0136] Add 50 mL of saturated Na2SO3 aqueous solution to the reaction system, stir for 15 min, then add 50 mL of water, shake to mix, let stand and separate the layers, collect the lower organic phase, dry with anhydrous Na2SO4 and filter. The obtained organic phase is used directly for the reductive amination reaction in step (2) without concentration or separation of (S)-3-chloro-2-hydroxypropanal.

[0137] (2) Transfer the organic phase obtained in step (1) to a 500 mL three-necked reaction flask, cool it to 0°C using an ice-water bath, add 200 mmol isopropylamine, stir for 30 min, and then add 150 mmol NaBH(OAc)3 in three batches. After the addition is complete, raise the temperature to 20°C and stir the reaction for 8 h.

[0138] After the reaction was completed, a saturated NaHCO3 aqueous solution was slowly added dropwise to quench the reaction. The mixture was allowed to stand, and the organic phase was separated and collected. The obtained organic phase was washed successively with 0.5 mol / L HCl aqueous solution, saturated NaHCO3 aqueous solution, and saturated NaCl aqueous solution. After drying with anhydrous Na2SO4 and filtration, 1,2-dichloroethane was removed under reduced pressure and low temperature to obtain 13.5 g of pale yellow oily crude (S)-1-chloro-3-isopropylamino-2-propanol, with a yield of 89%. The obtained crude product was used directly for the nucleophilic substitution reaction in step (3) without distillation purification.

[0139] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. Under nitrogen protection, 100 mmol of LDA (diisopropylaminolithium) was added dropwise below 0 °C to remove hydrogen. The temperature was then restored to 25 °C, and the mixture was stirred at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. 10 mmol of KI was then added. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h. After the addition was complete, a nucleophilic substitution reaction was carried out at 20 °C for 12 h, and the reaction was monitored by TLC.

[0140] After the reaction was completed and cooled to room temperature, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product, which was then recrystallized from ethyl acetate-petroleum ether to obtain 22.8 g of free S-caralol base, with a yield of 85%.

[0141] (4) Add 22.8 g of S-caralol free base obtained in step (3) to 200 mL of anhydrous ethanol, stir to dissolve, and then cool the system to 0℃. Slowly add 80 mL of 1 mol / L HCl-ethanol solution. After the addition is complete, continue to let it stand at 0℃ for crystallization for 8 h. Filter to collect the solid, wash with cold ethanol, and then recrystallize once with a 1:2 volume ratio ethanol-isopropanol mixed solvent. Dry under vacuum at 45℃ to obtain 22.48 g of white solid S-caralol hydrochloride, yield 88%, melting point: 243.7℃. 1 H NMR (500 MHz, DMSO) δ 11.46 (s, 1H), 9.14 (d, J = 173.9 Hz, 2H), 8.27 (d, J = 7.8 Hz, 1H), 7.69 – 6.87 (m, 5H), 6.71 (d, J = 7.9 Hz, 1H), 6.09(s, 1H), 4.51 (d, J = 4.7 Hz, 1H), 4.26 (ddd, J = 21.9, 9.8, 5.2 Hz, 2H), 3.45 – 3.25 (m, 2H), 3.15 (dd, J = 12.2, 9.7 Hz, 1H), 1.31 (t, J = 6.8 Hz, 6H); 13C NMR (500 MHz, DMSO) δ 154.99, 141.62, 139.46, 126.91, 125.08, 123.06, 122.05, 119.09, 111.98, 110.93, 104.69, 100.95, 70.11, 65.92,50.28, 47.56, 39.98, 39.81, 39.64, 39.48, 19.04, 18.69; HRMS calcd forC 18 H 23 N2O2 + [M + H] + 299.1775.

[0142] Example 2

[0143] The preparation method of S-caralol hydrochloride in Example 2 differs from that in Example 1 in that the nucleophilic substitution reaction in step (3) is at 0°C, specifically including the following steps:

[0144] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0145] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. Under nitrogen protection, 100 mmol of LDA (diisopropylaminolithium) was added dropwise below 0 °C for dehydrogenation. The temperature was then restored to 25 °C, and the mixture was stirred at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. 10 mmol of KI was then added. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h. After the addition was complete, a nucleophilic substitution reaction was carried out at 0 °C. The reaction was monitored by TLC. After 36 h, a small amount of raw material remained unreacted. The reaction was stopped and post-processing was performed.

[0146] After the reaction was completed, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product. The crude product was then recrystallized from ethyl acetate-petroleum ether to obtain 18.1 g of free S-caralol base, with a yield of 68%.

[0147] (4) Follow the steps (4) of Example 1 to obtain S-caralol hydrochloride.

[0148] Example 3

[0149] The preparation method of S-caralol hydrochloride in Example 3 differs from that in Example 1 in that step (3) uses KOH as a dehydrogenating agent, specifically including the following steps:

[0150] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0151] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. After nitrogen protection, 100 mmol of potassium hydroxide was added to remove hydrogen, and the temperature was restored to 25 °C. The mixture was stirred at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. 10 mmol of KI was then added. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h. After the addition was complete, a nucleophilic substitution reaction was carried out at 20 °C for 12 h, and the reaction was monitored by TLC.

[0152] After the reaction was completed and cooled to room temperature, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product, which was then recrystallized from ethyl acetate-petroleum ether to obtain 21.97 g of free S-caralol base, with a yield of 82%.

[0153] (4) Follow the steps (4) of Example 1 to obtain S-caralol hydrochloride.

[0154] Example 4

[0155] The difference between the preparation method of S-caralol hydrochloride in Example 4 and that in Example 1 is that the volume ratio of ethanol to isopropanol during recrystallization in step (4) is 1:3, specifically including the following steps:

[0156] (1)-(3) were carried out according to steps (1)-(3) of Example 1 to obtain S-caralol free base.

[0157] (4) Take 11.4 g of the free S-caralol base obtained in step (3), add it to 100 mL of anhydrous ethanol, stir to dissolve, cool the system to 0℃, and slowly add 40 mL of 1 mol / L HCl-ethanol solution. After the addition is complete, continue to let it stand at 0℃ for crystallization for 8 h, filter to collect the solid, wash with cold ethanol, and recrystallize once with a 1:3 volume ratio of ethanol-isopropanol mixed solvent. Dry under vacuum at 45℃ to obtain 10.86 g of white solid S-caralol hydrochloride, with a yield of 84.8%.

[0158] Example 5

[0159] The preparation method of S-caralol hydrochloride in Example 5 differs from that in Example 1 in that the crude (S)-1-chloro-3-isopropylamino-2-propanol is added to the phenolate system in one step in step (3), specifically including the following steps:

[0160] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0161] (3) Add 100 mmol of 4-hydroxycarbazole to a 250 mL reaction flask, add 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF, and under nitrogen protection, add 100 mmol of LDA (diisopropylaminolithium) dropwise below 0 °C to remove hydrogen. Then restore to 25 °C and stir at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. Add 10 mmol of KI. Add the crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) to the phenolate system at once. After the addition is complete, carry out a nucleophilic substitution reaction at 20 °C for 12 h, and monitor the reaction with TLC.

[0162] After the reaction was completed and cooled to room temperature, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product. The crude product was then recrystallized from ethyl acetate-petroleum ether to obtain 21.9 g of free S-caralol base, with a yield of 82.3%.

[0163] (4) Follow the steps (4) of Example 1 to obtain S-caralol hydrochloride.

[0164] Example 6

[0165] The preparation method of S-caralol hydrochloride in Example 6 differs from that in Example 1 in the amount of KI added in step (3), which specifically includes the following steps:

[0166] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0167] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. Under nitrogen protection, 100 mmol of LDA (diisopropylaminolithium) was added dropwise below 0 °C to remove hydrogen. The temperature was then restored to 25 °C, and the mixture was stirred at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. 5 mmol of KI was then added. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h. After the addition was complete, a nucleophilic substitution reaction was carried out at 20 °C for 12 h, and the reaction was monitored by TLC.

[0168] After the reaction was completed and cooled to room temperature, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product. The crude product was then recrystallized from ethyl acetate-petroleum ether to obtain 22.6 g of free S-caralol base, with a yield of 84.7%.

[0169] (4) Follow the steps (4) of Example 1 to obtain S-caralol hydrochloride.

[0170] Example 7

[0171] The preparation method of S-caralol hydrochloride in Example 7 differs from that in Example 1 in that the selective oxidation reaction temperature in step (1) is 5°C, specifically including the following steps:

[0172] (1) Add 100 mmol of (S)-3-chloro-1,2-propanediol with an ee value of 99% to a 250 mL three-necked reaction flask, add 120 mL of 1,2-dichloroethane, and then add 5 mmol of Fe(NO3)3·9H2O, 5 mmol of 4-OH-TEMPO and 10 mmol of NaCl in sequence to replace the air in the reaction system with oxygen. Stir the reaction at 5 °C. Monitor the reaction with TLC and stop the reaction when the starting material spot disappears.

[0173] Add 50 mL of saturated Na2SO3 aqueous solution to the reaction system, stir for 15 min, then add 50 mL of water, shake to mix, let stand and separate the layers, collect the lower organic phase, dry with anhydrous Na2SO4 and filter. The obtained organic phase is used directly for the reductive amination reaction in step (2) without concentration or separation of (S)-3-chloro-2-hydroxypropanal.

[0174] (2)-(4) were carried out according to steps (2)-(4) of Example 1 to obtain 14.5g of free S-caralol base with a yield of 54.3%, and further obtained S-caralol hydrochloride.

[0175] Example 8

[0176] The preparation method of S-caralol hydrochloride in Example 8 differs from that in Example 1 in that step (1) uses TEMPO as a nitrogen oxide free radical catalyst and air as an oxidant, specifically including the following steps:

[0177] (1) Add 100 mmol of (S)-3-chloro-1,2-propanediol with an ee value of 99% to a 250 mL three-necked reaction flask, add 120 mL of 1,2-dichloroethane, and then add 5 mmol of Fe(NO3)3·9H2O, 5 mmol of TEMPO and 10 mmol of NaCl in sequence. Stir at 20 °C and continuously purge with atmospheric air. Monitor the reaction with TLC and stop the reaction when the starting material spot disappears.

[0178] Add 50 mL of saturated Na2SO3 aqueous solution to the reaction system, stir for 15 min, then add 50 mL of water, shake to mix, let stand and separate the layers, collect the lower organic phase, dry with anhydrous Na2SO4 and filter. The obtained organic phase is used directly for the reductive amination reaction in step (2) without concentration or separation of (S)-3-chloro-2-hydroxypropanal.

[0179] (2)-(4) were carried out according to steps (2)-(4) of Example 1 to obtain S-caralol hydrochloride.

[0180] Example 9

[0181] The preparation method of S-caralol hydrochloride in Example 9 differs from that in Example 1 in the amount of isopropylamine added in step (2), which specifically includes the following steps:

[0182] (1) Following step (1) of Example 1, an organic phase containing (S)-3-chloro-2-hydroxypropanal was obtained.

[0183] (2) Transfer the organic phase obtained in step (1) to a 500 mL three-necked reaction flask, cool it to 0°C using an ice-water bath, add 300 mmol isopropylamine, stir for 30 min, and then add 150 mmol NaBH(OAc)3 in three batches. After the addition is complete, raise the temperature to 20°C and stir the reaction for 8 h.

[0184] After the reaction was completed, a saturated NaHCO3 aqueous solution was slowly added dropwise to quench the reaction. The mixture was allowed to stand, and the organic phase was separated and collected. The obtained organic phase was washed successively with 0.5 mol / L HCl aqueous solution, saturated NaHCO3 aqueous solution, and saturated NaCl aqueous solution. After drying with anhydrous Na2SO4 and filtration, 1,2-dichloroethane was removed under reduced pressure and low temperature to obtain 12.74 g of pale yellow oily crude (S)-1-chloro-3-isopropylamino-2-propanol, with a yield of 84%. The obtained crude product was not purified by distillation and was directly used for the nucleophilic substitution reaction in step (3).

[0185] (3)-(4) were carried out according to steps (3)-(4) of Example 1 to obtain S-caralol hydrochloride.

[0186] Example 10

[0187] The preparation method of S-caralol hydrochloride in Example 10 differs from that in Example 1 in that step (4) uses methanol as the organic solvent for the salt formation reaction, specifically including the following steps:

[0188] (1)-(3) were carried out according to steps (1)-(3) of Example 1 to obtain S-caralol free base.

[0189] (4) Take 11.4 g of the free S-caralol base obtained in step (3), add it to 100 mL of methanol, stir to dissolve, cool the system to 0℃, and slowly add 40 mL of 1 mol / L HCl-methanol solution. After the addition is complete, continue to let it stand at 0℃ for crystallization for 8 h, filter to collect the solid, wash with cold methanol, and recrystallize once with a 1:2 volume ratio ethanol-methanol mixed solvent. Dry under vacuum at 45℃ to obtain 10.6 g of white solid S-caralol hydrochloride, with a yield of 83%.

[0190] Comparative Example 1

[0191] The preparation method of S-caralol hydrochloride in Comparative Example 1 differs from that in Example 1 in that the nucleophilic substitution reaction temperature in step (3) is 50°C, specifically including the following steps:

[0192] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0193] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. Under nitrogen protection, 100 mmol of LDA (diisopropylaminolithium) was added dropwise below 0 °C for dehydrogenation. The temperature was then raised to 50 °C and stirred at 50 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. 10 mmol of KI was added. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h at 50 °C. After the addition was complete, a nucleophilic substitution reaction was carried out at 50 °C, and the reaction was monitored by TLC.

[0194] After the reaction was completed and cooled to room temperature, 200 mL of water was added to the reaction system, and the mixture was extracted twice with 200 mL of ethyl acetate. The ethyl acetate phases were combined, washed with water, washed with saturated NaCl aqueous solution, and dried with anhydrous Na2SO4. The mixture was then filtered and concentrated to obtain the crude product. The crude product was then recrystallized from ethyl acetate-petroleum ether to obtain 23.1 g of free S-caralol base, with a yield of 86.8%.

[0195] (4) Follow the steps (4) of Example 1 to obtain S-caralol hydrochloride.

[0196] Comparative Example 2

[0197] The preparation method of S-caralol hydrochloride in Comparative Example 2 differs from that in Example 1 in that step (3) does not involve the addition of Finkelstein halogen exchange catalyst, and specifically includes the following steps:

[0198] (1)-(2) were carried out according to steps (1)-(2) of Example 1 to obtain crude (S)-1-chloro-3-isopropylamino-2-propanol.

[0199] (3) 100 mmol of 4-hydroxycarbazole was added to a 250 mL reaction flask, along with 70 mL of anhydrous acetonitrile and 70 mL of anhydrous DMF. Under nitrogen protection, 100 mmol of LDA (diisopropylaminolithium) was added dropwise below 0 °C to remove hydrogen. The temperature was then restored to 25 °C, and the mixture was stirred at 25 °C for 1 h under nitrogen protection to form a phenolate system of 4-hydroxycarbazole. The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) was dissolved in 30 mL of anhydrous acetonitrile. The concentration of (S)-1-chloro-3-isopropylamino-2-propanol in the resulting solution was 3 mol / L. The phenolate system was added at a volumetric rate of 6 mL / h. After the addition was complete, a nucleophilic substitution reaction was carried out at 25 °C for 22 h. The reaction was monitored by TLC, and almost no reaction occurred at the end of the reaction.

[0200] The S-caralol free base prepared in Examples 1 to 3, Examples 5 to 6 and Comparative Example 1, the S-caralol hydrochloride prepared in Examples 1, 4 and 6 to 10, and the crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) of Example 9 were subjected to chiral high performance liquid chromatography to determine the ee value of the corresponding samples.

[0201] The S-caralol hydrochloride prepared in Examples 1 and 4 was subjected to high performance liquid chromatography (HPLC) to determine its HPLC purity; the samples obtained in step (3) of Examples 3 to 5 were subjected to HPLC to investigate the formation of epoxy impurities.

[0202] Chiral high-performance liquid chromatography (HPLC) detection was performed using an Agilent-1260 HPLC system. The chiral column was a Chira·NO(2)-RH5u·FMG-AC5-AO6-R250mm x 4.6mm, 5um column. The mobile phase was 0.1% phosphoric acid solution (adjusted to pH 8.0 with triethylamine):acetonitrile = 60:40. The flow rate was 1.0 mL / min, the column temperature was 25℃, the detection wavelength was 240nm, and the injection volume was 1.0 μL. A racemic mixture of caralol hydrochloride purchased from Beijing Bailingwei Technology Co., Ltd. was used as a control sample. Chiral HPLC detection was performed under the above conditions, and its chiral HPLC chromatogram is shown below. Figure 1 As shown; the chiral HPLC spectrum of S-caralol hydrochloride prepared in Example 1 is shown below. Figure 2 As shown.

[0203] High-performance liquid chromatography (HPLC) was performed using an Agilent ZORBAX SB-CN instrument (250 × 4.6 mm, 5 μm column). The mobile phase was ammonium acetate solution (pH 6.0): acetonitrile = 65:35. The flow rate was 1 mL / min, the column temperature was 35 °C, the detection wavelength was 240 nm, and the injection volume was 10 μL. Under the above HPLC conditions, the purity of S-caralol hydrochloride prepared in Example 1 was determined, and the resulting HPLC chromatogram is shown below. Figure 7 As shown.

[0204] High-resolution mass spectrometry (HRMS) detection was performed using an Agilent 6520 Q-TOF HRMS instrument in ESI positive ion mode. The HRMS spectrum of S-caralol hydrochloride prepared in Example 1 is shown below. Figure 3 As shown.

[0205] Nuclear magnetic resonance (NMR) detection was performed on S-caralol hydrochloride prepared in Example 1 using DMSO-d6 as the solvent. 1 HNMR and13 The obtained spectra from the C NMR detection are as follows: Figure 4 and Figure 5 As shown.

[0206] Differential scanning calorimetry (DSC) was performed using a differential scanning calorimeter. Approximately 1.79 mg of the S-caralol hydrochloride sample prepared in Example 1 was heated from 25°C to 300°C at a heating rate of 10°C / min. The resulting DSC curve is shown below. Figure 6 As shown.

[0207] Table 1. ee values ​​of S-caralol free bases prepared in the examples and comparative examples.

[0208]

[0209] Table 2. ee values ​​of S-caralol hydrochloride prepared in the examples

[0210]

[0211] Table 3. High Performance Liquid Chromatography Detection Results

[0212]

[0213] The crude (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) of Example 9 had an ee value of 98.6%. Figure 1 As can be seen, the racemic form of caralol hydrochloride showed two separate chromatographic peaks under the chiral high-performance liquid chromatography detection conditions, with retention times of 6.929 min and 8.503 min, peak area percentages of 49.69% and 50.31%, respectively, and a resolution of 3.8, indicating that the detection conditions could effectively separate the two enantiomers of caralol.

[0214] Depend on Figure 2 As can be seen, the S-caralol hydrochloride prepared in Example 1 showed a major chromatographic peak at a retention time of 6.935 min, which is consistent with... Figure 1 The chromatographic peak with a retention time of 6.929 min in the racemic mixture of caralol hydrochloride corresponds to this peak, while no obvious enantiomer peak was observed near 8.503 min. This indicates that the S-caralol hydrochloride prepared in Example 1 has high enantiomer purity.

[0215] Depend on Figure 3 As can be seen, the S-caralol hydrochloride prepared in Example 1 was detected by high-resolution mass spectrometry with a [M+H]⁺ ion peak at m / z 299.1755, and its ionic formula is C. 18 H 23The theoretical m / z of N2O2 is 299.1754, and the measured value is consistent with the theoretical value, indicating that the caralol molecules in the obtained product have the expected molecular composition.

[0216] Depend on Figure 4 and Figure 5 As can be seen, the ¹H NMR and ¹³C NMR spectra of S-caralol hydrochloride prepared in Example 1 show hydrogen and carbon signals corresponding to the structure of the target compound, which are basically consistent with the NMR detection results listed in Example 1, further indicating that the obtained product has the expected chemical structure.

[0217] Depend on Figure 6 As can be seen, the S-caralol hydrochloride prepared in Example 1 showed a significant endothermic peak at about 243.67℃, with an initial temperature of about 242.53℃, which is basically consistent with the melting point of 243.7℃ recorded in Example 1, indicating that the obtained product has the corresponding thermal characteristics.

[0218] Depend on Figure 7 As can be seen, the S-caralol hydrochloride prepared in Example 1 showed a main peak at a retention time of 16.032 min, with a main peak area percentage of 99.76%, while the area percentage of the remaining impurity peaks was low, indicating that the obtained S-caralol hydrochloride had high chemical purity.

[0219] As shown in Table 1, S-caralol can be prepared by nucleophilic substitution of (S)-1-chloro-3-isopropylamino-2-propanol with 4-hydroxycarbazole, which has a predetermined S configuration. Comparing Example 1 and Comparative Example 1, it is evident that, under essentially the same reaction conditions, increasing the nucleophilic substitution reaction temperature significantly affects the chiral retention of the product, indicating that using a lower temperature for nucleophilic substitution is beneficial for obtaining S-caralol with higher optical purity.

[0220] As can be seen from Examples 1, 3, and 5, the type of hydrogen-removing reagent and the feeding method of (S)-1-chloro-3-isopropylamino-2-propanol affect the chirality of the product and the epoxy side reaction. Using LDA (lithium diisopropylamino) as the hydrogen-removing reagent and controlling the feeding of (S)-1-chloro-3-isopropylamino-2-propanol helps maintain the chirality of the product and reduce the epoxy side reaction.

[0221] As can be seen from Examples 1 and 6 and Comparative Example 2, under the investigated conditions, the addition of KI is beneficial to the low-temperature nucleophilic substitution reaction; without the addition of Finkelstein halogen exchange catalyst, the reaction hardly occurred after 22 h at 25°C. Examples 1 and 6 further demonstrate that S-caralol with high optical purity can be obtained under different amounts of KI investigated, indicating that KI is well applicable to the aforementioned low-temperature nucleophilic substitution system.

[0222] As can be seen from Examples 7 to 9, after adjusting the reaction conditions of the selective oxidation and reductive amination steps, the resulting intermediate can still be smoothly connected to the subsequent nucleophilic substitution and salt formation processes. In particular, the chirality test results of the intermediate in Example 9 further indicate that the chirality of the intermediate can be well maintained during the reductive amination process. This demonstrates that the route for preparing (S)-1-chloro-3-isopropylamino-2-propanol from (S)-3-chloro-1,2-propanediol via selective oxidation and reductive amination has good process adaptability.

[0223] As can be seen from Examples 4 and 10, S-caralol hydrochloride with high optical purity can be obtained by using different salt-forming solvents and recrystallization conditions. Combined with the HPLC purity test results in Table 3, it can be seen that the salt-forming and recrystallization process can also obtain S-caralol hydrochloride with high chemical purity, indicating that the process has good process adaptability.

[0224] The above results indicate that low-temperature nucleophilic substitution of (S)-1-chloro-3-isopropylamino-2-propanol with 4-hydroxycarbazole, possessing a predetermined S-configuration, can yield S-caralol with high optical purity. The nucleophilic substitution reaction temperature has a significant impact on the retention of the product's chirality. Furthermore, the use of LDA (diisopropylaminolithium), KI, and controlled feeding further helps maintain the product's chirality and reduce the tendency for epoxide side reactions. The (S)-1-chloro-3-isopropylamino-2-propanol can also be obtained through selective oxidation and reductive amination of (S)-3-chloro-1,2-propanediol. The resulting S-caralol, after salt formation and recrystallization, yields S-caralol hydrochloride with high optical and chemical purity.

[0225] The specific embodiments described herein are merely illustrative of the technical concept of the present invention. Those skilled in the art to which this invention pertains may make various modifications, additions, or similar substitutions to the described specific embodiments without departing from the spirit of the invention and the scope defined by the appended claims.

Claims

1. A process for the preparation of S-carnitine, characterized in that, Includes the following steps: 4-Hydroxycarbazole was prepared into a solution with a concentration of 0.2~1 mol / L. The phenolic hydroxyl group of 4-hydroxycarbazole was subjected to dehydrogenation treatment with a dehydrogenation reagent under inert gas protection and stirred at 0~30℃ for 0.5~3 h to obtain a phenolic salt system. The hydrogen removal reagent used is any one or more of the following: sodium hydroxide, sodium carbonate, lithium hydroxide, lithium carbonate, cesium carbonate, sodium hydride, potassium hydroxide, potassium carbonate, lithium diisopropylamino, lithium hexamethyldisilamino, sodium hexamethyldisilamino, potassium hexamethyldisilamino, methyllithium, and n-butyllithium. Based on the molar amount of the 4-hydroxycarbazole, the amount of the dehydrogenating agent is 0.5 to 2 equivalents; (2) Add Finkelstein halide exchange catalyst to the phenolic salt system, then add (S)-1-chloro-3-isopropylamino-2-propanol, and carry out nucleophilic substitution reaction at 0~30℃ for 8~36 h to obtain S-caralol; The Finkelstein halogen exchange catalyst is selected from any one or more of potassium iodide, sodium iodide, and tetrabutylammonium iodide; the amount of the Finkelstein halogen exchange catalyst is 5 to 30 mol based on the molar amount of the 4-hydroxycarbazole.

2. The process for the preparation of S-ketoprofen according to claim 1, characterized in that, The (S)-1-chloro-3-isopropylamino-2-propanol was prepared into a (S)-1-chloro-3-isopropylamino-2-propanol solution with a concentration of 0.2~3 mol / L, and added to the reaction system that had undergone dehydrogenation treatment and contained Finkelstein halogen exchange catalyst at a volume feed rate of 1~10 mL / h to carry out a nucleophilic substitution reaction.

3. The process for the preparation of S-ketoprofen according to claim 1, characterized in that, The (S)-1-chloro-3-isopropylamino-2-propanol was prepared by the following method: (1) In the presence of iron salt, nitrogen and oxygen free radical catalyst and regulator, the terminal primary hydroxyl group of (S)-3-chloro-1,2-propanediol is oxidized by using any one or two of air and oxygen as oxidant to obtain (S)-3-chloro-2-hydroxypropanal. (2) The (S)-3-chloro-2-hydroxypropanal obtained in step (1) is subjected to reductive amination with isopropylamine in the presence of a reducing agent to obtain the (S)-1-chloro-3-isopropylamino-2-propanol.

4. The method for preparing S-caralol according to claim 3, characterized in that, In step (1), the solvent for oxidation is 1,2-dichloroethane, and the reaction temperature is 0~30℃; And / or, after the oxidation reaction in step (1) is completed, an organic phase containing the (S)-3-chloro-2-hydroxypropanal is obtained by quenching and separation. The organic phase is used directly for the reductive amination in step (2) without concentration or separation of the (S)-3-chloro-2-hydroxypropanal. And / or, in step (2), the reaction temperature of the reductive amination is 0~25℃; And / or, the (S)-1-chloro-3-isopropylamino-2-propanol obtained in step (2) is used directly for the nucleophilic substitution reaction without distillation purification.

5. The process for the preparation of S-ketalarol according to claim 3, characterized in that, The iron salt is ferric nitrate nonahydrate; And / or, the nitric oxide radical catalyst is selected from any one or more of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxo radical and 2,2,6,6-tetramethylpiperidine oxide; And / or, the regulator is selected from any one or both of sodium chloride and lithium chloride; And / or, the reducing agent is selected from any one or more of sodium triacetoxyborohydride, sodium cyanoborohydride, and sodium borohydride.

6. The process for the preparation of S-ketalarol according to claim 5, characterized in that, The nitrogen oxide free radical catalyst is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxo radical, the regulator is sodium chloride, and the reducing agent is sodium triacetoxyborohydride. Based on the molar amount of (S)-3-chloro-1,2-propanediol, the amount of iron nitrate nonahydrate is 5-20 mol%, the amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxo radical is 2-30 mol%, the amount of sodium chloride is 5-20 mol%, the amount of isopropylamine is 100-300 mol%, and the amount of sodium triacetoxyborohydride is 100-300 mol.

7. S-carnitine characterized in that, The S-caralol was prepared by the method described in claim 1.

8. S-carisbamate characterized in that, The preparation method of the S-caralol hydrochloride includes the following steps: The S-caralol obtained by the preparation method according to claim 1 is reacted with hydrogen chloride in an organic solvent to form a salt, and then recrystallized to obtain S-caralol hydrochloride.

Citation Information

Patent Citations

  • Synthetic methods of chiral aryloxy propanol amine compounds and salts thereof

    CN101323580A

  • Process for the preparation of optically-active carbazole derivatives, new R- and S-carbazole derivatives and pharmaceutical compositions containing these compounds

    US4697022A